Note: This article is a data reference compiled from publicly available Australian Government sources (AIHW, ABS). It is intended for general informational and research purposes. All figures are sourced from the primary references linked throughout. This article does not constitute medical advice.
When Australian health policymakers, researchers, and clinicians discuss the obesity burden, they draw from a fragmented evidence base: AIHW National Health Surveys, ABS population estimates, Productivity Commission cost modelling, and standalone cohort studies that use different BMI thresholds and collection periods. This page consolidates that data into a single structured reference — adult and childhood prevalence by age, sex, state, and remoteness; economic cost estimates; long-run trends from 1995 to 2022; and the projected population-level impact of GLP-1 receptor agonist pharmacotherapy on Australian obesity rates.
For the analysis behind these numbers (why conventional interventions fall short and what the emerging metabolic science means for policy) see our companion evidence article, The Obesity Crisis in Australia: What the Evidence Tells Us. This statistics reference is intended to be cited alongside it: the pillar explains the why, this page documents the what.
Key Figures at a Glance
| Metric | Figure | Source |
|---|---|---|
| Adults overweight or obese | 66% (2022) | AIHW NHS 2022 |
| Adults with obesity (BMI ≥30) | 32% (2022) | AIHW NHS 2022 |
| Adults overweight but not obese | 34% (2022) | AIHW NHS 2022 |
| Children aged 2–17 overweight or obese | 26% (2022) | AIHW NHS 2022 |
| Adults overweight or obese in 1995 | 57% | AIHW trend data |
| Adults with obesity in 1995 | 19% | AIHW trend data |
| Estimated economic cost | $11.8B (2017–18) | AIHW |
| Outer regional/remote adults overweight or obese | 70% (2022) | AIHW NHS 2022 |
Prevalence: Adults
The 2022 ABS National Health Survey (NHS), the most recent nationally representative measured dataset, found that 66% of Australian adults aged 18 and over were living with overweight or obesity. This breaks down as:
- 32% living with obesity (BMI ≥30)
- 34% overweight but not obese (BMI 25–29.9)
The figure has remained broadly stable since 2017–18 (67%), though the long-run trend since 1995 shows a marked rise (see the trends section below).
By Sex
Obesity prevalence differed by sex in the 2022 NHS data:
- Men: higher overall rates of overweight (but not obesity) compared with women
- Women: similar obesity rates to men, with divergence by age group
Among young adults aged 18–24, obesity prevalence was 15% in men and 16% in women. By ages 65–74, this rose to 41% in men and 37% in women, a near-tripling across the lifespan that reflects the cumulative nature of weight gain associated with ageing, reduced metabolic rate, and lifestyle changes.
By Age Group
Obesity becomes progressively more prevalent with age:
- Ages 18–24: ~15–16%
- Ages 45–54: significantly elevated above the young-adult baseline
- Ages 65–74: 37–41%, the peak age band for obesity prevalence in Australia
This gradient has consistent implications for chronic disease burden: cardiovascular disease, type 2 diabetes, sleep apnoea, osteoarthritis, and certain cancers all track closely with BMI and abdominal adiposity, and all increase in incidence with age.
Prevalence: Children and Adolescents
One in four Australian children and adolescents (aged 2–17), or 26%, were living with overweight or obesity in 2022, according to AIHW data. This proportion has remained stable since 2017–18, suggesting the upward trajectory seen in previous decades has plateaued, though not reversed.
Key sub-group findings:
- Lowest socioeconomic areas: 34% of children aged 2–17 were overweight or obese
- Highest socioeconomic areas: 21%, a 13 percentage point gap driven by differential access to nutritious food, safe physical activity environments, and health literacy
- Aboriginal and Torres Strait Islander children (aged 2–17): 38% living with overweight or obesity (ABS 2018–19 National Aboriginal and Torres Strait Islander Health Survey, the most recent available for this cohort)
The socioeconomic and Indigenous health equity gaps in childhood obesity are well documented in AIHW's dedicated childhood obesity report and are considered priority areas in the National Preventive Health Strategy.
Geographic Variation
Geography is among the strongest predictors of obesity prevalence in Australian adults. After adjusting for age, the 2022 NHS data shows:
| Remoteness Category | Adults Overweight or Obese |
|---|---|
| Major cities | 64% |
| Inner regional | 68% |
| Outer regional and remote | 70% |
The gap between major cities and outer regional/remote areas (6 percentage points) reflects structural barriers: reduced access to fresh food, fewer recreational facilities, greater reliance on motorised transport, and higher rates of socioeconomic disadvantage.
Primary Health Network (PHN) Variation
Within-state variation is substantial. Among PHN areas:
- Highest prevalence: Western New South Wales PHN, at 79% of adults living with overweight or obesity (age-adjusted)
- Lowest prevalence: Northern Sydney PHN, at approximately 46% of adults
This 33 percentage point range between PHN areas illustrates that population-level averages obscure significant local variation. Rural and remote communities carry a disproportionately high burden, yet have the least access to specialist weight management services, dietitians, and, most recently, GLP-1 prescribers with appropriate obesity medicine training.
Long-Run Trends: 1995 to 2022
Australia has tracked overweight and obesity prevalence through nationally representative surveys since the mid-1990s. Age-standardised trend data from AIHW shows a clear and sustained increase over nearly three decades:
| Year | Overweight or Obese | Obesity Only |
|---|---|---|
| 1995 | 57% | 19% |
| 2007–08 | 61% | 25% |
| 2011–12 | 63% | 28% |
| 2017–18 | 67% | 31% |
| 2022 | 65% | 32% |
The slight dip in the combined overweight-or-obese figure between 2017–18 and 2022 reflects a modest decline in the overweight-but-not-obese category (from 36% to 34%), while obesity itself continued to rise incrementally (31% to 32%). The data does not suggest a reversal of the obesity trend; rather, some people previously classified as overweight have crossed into the obese category.
Over the full period, the proportion of adults with obesity has grown from 19% to 32%, a 68% relative increase across 27 years.
Economic and Health Burden
Healthcare Costs
AIHW estimated that overweight and obesity cost the Australian economy approximately $11.8 billion in total costs in 2017–18. This figure encompasses direct healthcare expenditure (hospital admissions, GP visits, medications, specialist care) plus indirect costs (productivity losses, carer burden, and premature mortality).
More recent modelling, including analysis widely cited in policy discussions, projected Australia's total obesity-related economic cost at approximately AUD $39 billion (approximately 1.9% of GDP) as of 2019, with projections suggesting this could rise substantially through the 2030s if trends continue unchanged.
Disease Burden
The AIHW Australian Burden of Disease framework, which measures years of healthy life lost to illness, disability, and premature death, identifies overweight and obesity as one of the leading attributable risk factors for chronic disease in Australia. The conditions most strongly linked to excess adiposity include:
- Type 2 diabetes: the strongest individual association; excess body weight accounts for a majority of attributable risk
- Cardiovascular disease: coronary heart disease, stroke, and heart failure
- Sleep apnoea and respiratory conditions
- Osteoarthritis: joint loading from excess weight accelerates cartilage degradation
- Certain cancers: endometrial, oesophageal, kidney, pancreatic, colorectal, and post-menopausal breast cancers all carry elevated risk with obesity
- Mental health conditions: bidirectional relationship with depression and anxiety
For a detailed breakdown of how excess adiposity drives metabolic dysfunction at the tissue level, see our guide to visceral fat and metabolic risk.
Childhood Obesity: Longer-Term Implications
The 26% prevalence of overweight or obesity among Australian children aged 2–17 is not simply a paediatric health issue; it has direct consequences for adult disease burden. AIHW's birth cohort analysis of overweight and obesity trajectories demonstrates strong tracking: children with obesity are significantly more likely to carry excess weight into adulthood, and to develop associated cardiometabolic conditions earlier.
The socioeconomic gradient is pronounced: children from the lowest-income areas are more likely to be living with overweight or obesity, a 34% vs 21% gap compared to the highest socioeconomic areas. This gap compounds across generations and underlies Australia's persistent health equity disparities.
GLP-1 Medications: What They Mean for Population Trends
The emergence of GLP-1 receptor agonist medications, semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), represents the first pharmacological intervention with clinically meaningful effect sizes on obesity at scale. Clinical trials demonstrate average body weight reductions of 10–15% with semaglutide and 15–21% with tirzepatide, substantially exceeding prior pharmacotherapy.
Australia's PBS listing of Wegovy in 2025 was a structural shift in treatment access, though eligibility criteria (BMI ≥30, or ≥27 with comorbidities) and prescriber capacity constraints mean population-level impact will take years to materialise. For more on which medications are currently subsidised and eligible criteria, see PBS weight loss medications in Australia.
Global modelling does not yet support confident projections that GLP-1 availability alone will reverse Australia's obesity prevalence trajectory. The WHO's 2025 guideline on GLP-1 therapies for obesity acknowledges these medicines as one tool within a broader, system-level chronic-care response, explicitly framing them as part of a model that also depends on structural food environment and physical activity policy rather than medication alone.
To understand the biological mechanisms behind why these medications work, see how GLP-1 agonists work.
Key factors constraining population-level impact in Australia:
- PBS eligibility requirements: approximately 32% of adults meet the obesity-only threshold (BMI ≥30), but access requires an eligible prescriber and an active treatment plan
- Discontinuation rates: real-world data shows significant medication discontinuation within 12 months, with weight regain on cessation
- Supply constraints: global semaglutide shortages have periodically disrupted Australian supply
- Access equity: current prescribing is concentrated in metropolitan, higher-income populations, replicating the inverse care law observed across Australian healthcare
Data Limitations and Measurement Notes
Most Australian national obesity statistics rely on self-reported or measured BMI from the ABS National Health Survey. Key limitations include:
- BMI as a population measure: BMI does not distinguish fat mass from lean mass, and misclassifies some individuals (particularly those with high muscle mass or older adults with sarcopenic obesity). However, at population level, BMI remains the most practical and internationally comparable measure.
- Self-report bias: In surveys using self-reported height and weight, obesity prevalence is typically underestimated by 2–5 percentage points compared with measured data.
- Survey frequency: The NHS is conducted infrequently (not annual), meaning the 2022 data remains the most current measured dataset as of mid-2026.
- Indigenous health data: The most recent dedicated ABS health survey for Aboriginal and Torres Strait Islander peoples dates to 2018–19; more recent estimates are modelled, not directly measured.
Summary
Australia's obesity burden in 2026 is characterised by:
- High and stable adult prevalence: 66% overweight or obese, 32% obese, little change since 2017–18
- A strong long-run upward trend: from 57% (1995) to 65–67% (2017–22), with obesity nearly doubling from 19% to 32%
- Marked geographic and socioeconomic inequity: outer regional/remote adults 6 percentage points above city rates; PHN variation spans 33 percentage points
- Significant childhood burden: 1 in 4 children affected, with larger proportions in low-income and Indigenous communities
- Substantial economic cost: at least $11.8 billion annually in measured healthcare costs
- Emerging pharmacotherapy: GLP-1 medications are a genuine clinical advance but insufficient alone to reverse population trends without structural reform
Primary Sources
- AIHW, Overweight and obesity (summary, 2022 NHS data): https://www.aihw.gov.au/reports/overweight-obesity/overweight-and-obesity/contents/summary
- AIHW, Overweight and obesity among Australian children and adolescents: https://www.aihw.gov.au/reports/overweight-obesity/overweight-obesity-australian-children-adolescents/summary
- AIHW, A picture of overweight and obesity in Australia: https://www.aihw.gov.au/reports/overweight-obesity/a-picture-of-overweight-and-obesity-in-australia/summary